Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: Evaluation of CYP2C9*2/*3 polymorphisms

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 3, 2006, Pages 285-287

  Toriello, Mario ^a   Meccariello, Pasquale ^b   Mazzaccara, Cristina ^a,b   Di Fiore, Rosanna ^a,b   Esposito, Carmela ^b   Sacchetti, Lucia ^a,b  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cytochrome P450 (CYP450); Pharmacogenetic testing; Polymorphisms

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ACCURACY; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; HUMANS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SENSITIVITY AND SPECIFICITY; TAQ POLYMERASE; TEMPERATURE;

EID: 33644821004     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.049     Document Type: Article

References (12)

1. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 2005;15:365-9.
2. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interaction and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005;45:477-94.
3. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P4502C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16.
4. You JHS, Chan FWH, Wong RSM, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thromb Haemost 2004;92:590-7.
5. Takahashi H, Wilkinson GR, Padrini R, Echizen H. CYP2C9 and oral anticoagulation therapy with acenocumarol and warfarin: similarities yet differences. Clin Pharmacol Ther 2004;75:376-80.
6. Jannetto PJ, Laleli-Sahin E, Wong SH. Pharmacogenomics genotyping methodologies. Clin Chem Lab Med 2004;42:1256-64.
7. Yang JQ, Morin S, Verstuyft C, Fan LA, Zhang Y, Di Xu C, et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 2003;17:373-6.
8. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′-nuclease assay. Genet Anal 1999;14:143-9.
9. Burian M, Grösch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. J Clin Pharmacol 2002;54:518-21.
10. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 1997;245:154-60.
11. Spreafico M, Peyvandi F, Pizzotti D, Moia M, Mannucci M. Warfarin and acenocumarol dose requirements according to CYP2C9 genotype in North-Italian patients [letter]. J Thromb Haemost 2004;1:2252-3.
12. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195-200.